Gilead acquired global rights to Genhouse Bio’s clinic-ready MAT2A-targeting synthetic‑lethality candidate GH31, paying $80 million upfront and up to $1.45 billion in milestones plus double-digit royalties. Genhouse has IND clearance in China and the U.S., positioning GH31 for rapid clinical advancement. Gilead framed the deal as part of a disciplined oncology expansion strategy. The transaction highlights continued major pharma appetite for synthetic‑lethality programs and cross-border licensing from Chinese biotech. For drug developers, the deal sets a commercial reference for early-stage MAT2A assets and signals strong M&A interest in mechanism-driven oncology candidates with IND-enabling data.